دورية أكاديمية
Presentation of Graves orbitopathy within European Group On Graves Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)
| العنوان: | Presentation of Graves orbitopathy within European Group On Graves Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III) |
|---|---|
| المؤلفون: | Schuh, Anna, Ayvaz, Goksun, Baldeschi, Lelio, Baretic, Maja, Bechtold, Dorte, Boschi, Antonella, Brix, Thomas Heiberg, Burlacu, Maria-Cristina, Ciric, Jasmina, Covelli, Danila, Currò, Nicola, Donati, Simone, Eckstein, Anja K, Fichter, Nicole, Führer, Dagmar, Horn, Maren, Jabłonska-Pawlak, Anna, Juri Mandic, Jelena, Kahaly, George J, Konuk, Onur, Langbein, Amelie, Lanzolla, Giulia, Marcocci, Claudio, Marinò, Michele, Miskiewicz, Piotr, Beleslin, Biljana Nedeljkovic, Pérez-Lázaro, Antonia, Pérez-López, Marta, Ponto, Katharina A, Quinn, Anthony, Rudofsky, Gottfried, Salvi, Mario, Schittkowski, Michael P, Tanda, Maria Laura, Toruner, Fusun, Vaidya, Bijay, Hintschich, Christoph R |
| بيانات النشر: | BMJ Publishing Group Ltd |
| سنة النشر: | 2024 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | Oculoplastic and orbit |
| الوصف: | Background Graves’ orbitopathy (GO) is subject to epidemiological and care-related changes. Aim of the survey was to identify trends in presentation of GO to the European Group On Graves’ Orbitopathy (EUGOGO) tertiary referral centres and initial management over time. Methods Prospective observational multicentre study. All new referrals with diagnosis of GO within September–December 2019 were included. Clinical and demographic characteristics, referral timelines and initial therapeutic decisions were recorded. Data were compared with a similar EUGOGO survey performed in 2012. Results Besides age (mean age: 50.5±13 years vs 47.7±14 years; p 0.007), demographic characteristics of 432 patients studied in 2019 were similar to those in 2012. In 2019, there was a decrease of severe cases (9.8% vs 14.9; p<0.001), but no significant change in proportion of active cases (41.3% vs 36.6%; p 0.217). After first diagnosis of GO, median referral time to an EUGOGO tertiary centre was shorter (2 (0–350) vs 6 (0–552) months; p<0.001) in 2019. At the time of first visit, more patients were already on antithyroid medications (80.2% vs 45.0%; p<0.001) or selenium (22.3% vs 3.0%; p<0.001). In 2019, the initial management plans for GO were similar to 2012, except for lid surgery (2.4% vs 13.9%; p<0.001) and prescription of selenium (28.5% vs 21.0%; p 0.027). Conclusion GO patients are referred to tertiary EUGOGO centres in a less severe stage of the disease than before. We speculate that this might be linked to a broader awareness of the disease and faster and adequate delivered treatment. |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | http://bjo.bmj.com/cgi/content/short/108/2/294Test; http://dx.doi.org/10.1136/bjo-2022-322442Test |
| DOI: | 10.1136/bjo-2022-322442 |
| الإتاحة: | https://doi.org/10.1136/bjo-2022-322442Test http://bjo.bmj.com/cgi/content/short/108/2/294Test |
| حقوق: | Copyright (C) 2024, BMJ Publishing Group Ltd |
| رقم الانضمام: | edsbas.B86B6E9E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/bjo-2022-322442 |
|---|